PharmaCorp Rx Inc. (TSXV:PCRX)

PharmaCorp Rx Statistics

Total Valuation

PharmaCorp Rx has a market cap or net worth of CAD 85.30 million. The enterprise value is 64.31 million.

Market Cap	85.30M
Enterprise Value	64.31M

Important Dates

The next estimated earnings date is Thursday, May 14, 2026.

Earnings Date	May 14, 2026
Ex-Dividend Date	n/a

Share Statistics

PharmaCorp Rx has 174.08 million shares outstanding. The number of shares has increased by 53.12% in one year.

Current Share Class	174.08M
Shares Outstanding	174.08M
Shares Change (YoY)	+53.12%
Shares Change (QoQ)	+26.75%
Owned by Insiders (%)	11.17%
Owned by Institutions (%)	6.23%
Float	147.47M

Valuation Ratios

PE Ratio	n/a
Forward PE	49.00
PS Ratio	4.08
PB Ratio	1.63
P/TBV Ratio	3.93
P/FCF Ratio	44.46
P/OCF Ratio	42.51
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-43.41
EV / Sales	3.08
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	33.52

Financial Position

The company has a current ratio of 5.14, with a Debt / Equity ratio of 0.09.

Current Ratio	5.14
Quick Ratio	4.67
Debt / Equity	0.09
Debt / EBITDA	n/a
Debt / FCF	2.37
Interest Coverage	-21.77

Financial Efficiency

Return on equity (ROE) is -3.43% and return on invested capital (ROIC) is -4.10%.

Return on Equity (ROE)	-3.43%
Return on Assets (ROA)	-1.54%
Return on Invested Capital (ROIC)	-4.10%
Return on Capital Employed (ROCE)	-2.07%
Weighted Average Cost of Capital (WACC)	-18.38%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.41
Inventory Turnover	6.27

Taxes

In the past 12 months, PharmaCorp Rx has paid 586,257 in taxes.

Income Tax	586,257
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +0.00% in the last 52 weeks. The beta is -4.30, so PharmaCorp Rx's price volatility has been lower than the market average.

Beta (5Y)	-4.30
52-Week Price Change	+0.00%
50-Day Moving Average	0.44
200-Day Moving Average	0.46
Relative Strength Index (RSI)	55.40
Average Volume (20 Days)	155,973

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, PharmaCorp Rx had revenue of CAD 20.89 million and -1.48 million in losses. Loss per share was -0.01.

Revenue	20.89M
Gross Profit	8.30M
Operating Income	-1.24M
Pretax Income	-835,800
Net Income	-1.48M
EBITDA	-414,759
EBIT	-1.24M
Loss Per Share	-0.01

Balance Sheet

The company has 25.89 million in cash and 4.55 million in debt, with a net cash position of 21.34 million or 0.12 per share.

Cash & Cash Equivalents	25.89M
Total Debt	4.55M
Net Cash	21.34M
Net Cash Per Share	0.12
Equity (Book Value)	52.27M
Book Value Per Share	0.30
Working Capital	24.08M

Cash Flow

In the last 12 months, operating cash flow was 2.01 million and capital expenditures -87,602, giving a free cash flow of 1.92 million.

Operating Cash Flow	2.01M
Capital Expenditures	-87,602
Depreciation & Amortization	822,933
Net Borrowing	2.84M
Free Cash Flow	1.92M
FCF Per Share	0.01

Margins

Gross margin is 39.72%, with operating and profit margins of -5.92% and -7.09%.

Gross Margin	39.72%
Operating Margin	-5.92%
Pretax Margin	-4.00%
Profit Margin	-7.09%
EBITDA Margin	-1.99%
EBIT Margin	-5.92%
FCF Margin	9.18%

Dividends & Yields

PharmaCorp Rx does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-53.12%
Shareholder Yield	-53.12%
Earnings Yield	-1.74%
FCF Yield	2.25%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

PharmaCorp Rx has an Altman Z-Score of 3.32 and a Piotroski F-Score of 4.

Altman Z-Score	3.32
Piotroski F-Score	4